

Clinical Dilemmas in


Inflammatory Bowel Disease


New Challenges

Second Edition

Edited by Peter Irving, Corey Siegel, David Rampton
and Fergus Shanahan



 WILEY-BLACKWELL



Clinical Dilemmas in

Inflammatory Bowel Disease

New Challenges

Second Edition

Edited by Peter Irving, Corey Siegel, David Rampton and Fergus Shanahan



Contents

Cover

Title Page

Copyright

Contributors

Preface

Part I: Genes and Phenotype in IBD

*Chapter 1: Which will take us further
in IBD—study of coding variation or
epigenetics?*

*Gene expression: sequence variation versus
epigenetic factors*

Genetic variation in IBD

Regulation of gene expression in IBD

*Limitations of current studies of epigenetic
mechanisms in IBD*

Conclusions

Chapter 2: IBD in different ethnic groups: same or different?

Introduction

Genotype

Phenotype

Dysplasia in UC

Extraintestinal Manifestations

Conclusions

Part II: Bugs and IBD—Good, Bad, or Indifferent?

Chapter 3: How does the risk of infection influence management of IBD around the world?

Introduction

Acute bacterial and parasitic infections mimicking IBD flare

Influence of IBD therapies on the risk of infection

Conclusion

Chapter 4: Traveling with IBD

Introduction

IBD, infections, and vaccination

Pretravel preparation

Chapter 5: What to do about hepatitis B and hepatitis C in patients with IBD

Introduction

IBD and chronic viral hepatitis

Effect of treatment for IBD on viral hepatitis

Treatment of IBD in patients with HBV

Treatment of IBD in patients with HCV

Treatment of viral hepatitis—effect of interferon on IBD

Conclusions

Chapter 6: CMV in IBD—passenger or pathogen?

Introduction

Diagnosis of CMV infection

Conclusions and recommendations

Chapter 7: Clostridium difficile in IBD: impact, prevention, and treatment

Introduction

Prevalence and impact

Presentation and assessment

Diagnosis

Prognosis

Treatment

Prevention

Conclusions

Chapter 8: Prebiotics and synbiotics: panacea or placebo

Introduction: the pathogenesis of inflammatory bowel disease (IBD)

The microbiota in IBD

Probiotics in IBD

Prebiotics and synbiotics: introduction

Conclusions

Chapter 9: Worms: light at the end of their burrow

Introduction

Hygiene hypothesis/rational for helminthic therapy

Conclusion

Chapter 10: Do we really need to vaccinate all patients with IBD?

What constitutes immunocompromised status?

Conclusion

Part III: Investigating IBD

Chapter 11: Biomarkers in IBD: myth or marvel?

Introduction

Classical biomarkers

Fecal biomarkers

Emerging serological biomarkers

Conclusions

Chapter 12: Radiation exposure in IBD: how do we minimize the dangers?

Introduction

Radiation exposure in IBD

Radiation exposure and CT

Alternative imaging strategies for minimizing radiation exposure

Improving referral practices

Conclusion

Chapter 13: Surveillance colonoscopy in UC: what is the best way to do it?

Introduction

Risk stratification

Surveillance colonoscopy

Dysplasia management

Conclusion

Part IV: Medical Therapy

5-ASA

Chapter 14: New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?

Introduction

Mechanism of action and pharmacology of different formulations

Efficacy and safety of aminosalicylates for UC

Conclusion

Chapter 15: Do 5-ASAs prevent cancer?

Introduction

How might 5-ASAs protect against CRC in UC?

What is the clinical and observational evidence?

Might other drugs be chemopreventive?

Conclusion

Chapter 16: Why do we still use 5-ASAs in Crohn's disease?

Introduction

Role in inducing remission

Role in maintaining remission

Role in maintaining remission in postoperative patients

Role in chemoprevention for colorectal cancer (CRC) prevention

Conclusions

Steroids

Chapter 17: Steroids in Crohn's disease: do the benefits outweigh the dangers?

Introduction

Benefits of steroids

Limitations of therapeutic effects of steroids

Adverse effects of steroids

Co-administration of immunomodulators with steroids

Role of anti-TNF therapies

The place of steroids in treatment of Crohn's disease

Immunomodulators

Chapter 18: Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?

Introduction

Thiopurine metabolism and the role of metabolite monitoring

Indications for the measurement of thiopurine metabolites

Conclusions

Chapter 19: Thiopurines and the sun: what should be done?

Introduction

Thiopurines and the sun: what is the risk?

Molecular mechanisms of thiopurine-associated skin cancer

What should be done?

Conclusions

Acknowledgements

Chapter 20: Do thiopurines worsen risk and prognosis of cervical neoplasia?

Introduction

Thiopurines and cancer risk

The risk of cervical cancer in thiopurine-treated IBD

The prognosis of cervical cancer in thiopurine-treated IBD

AZA in patients with a history of cervical cancer

Conclusion

Minimizing risks

Chapter 21: Optimizing use of methotrexate

Introduction

Lessons from pharmacology of methotrexate [1,2]

Efficacy in IBD

Adverse effects

Conclusions (Table 21.1)

Chapter 22: Which calcineurin inhibitor and when?

Introduction

Cyclosporine in UC

Tacrolimus in UC

Pharmacology

Toxicity

When to start a calcineurin inhibitor

Conclusions

Biologics

Chapter 23: Are all anti-TNF agents the same?

Introduction

Structure and function

Pharmacokinetic properties

Immunogenicity

Clinical efficacy

Conclusions

Chapter 24: One drug or two: do patients on biologics need concurrent immunomodulation?

Introduction

Efficacy of combination therapy

Conclusion

Chapter 25: How do we identify patients needing early aggressive therapy and what should we use?

Introduction

Clinical factors identifying complicated disease

Biomarkers for predicting complicated disease

Genetic markers of complicated disease

What should we use in patients identified as requiring early aggressive therapy?

Conclusion

Chapter 26: What is the role of biologics in UC?

Introduction

When to initiate a biologic for UC

Which drug(s) to initiate

The use of biologics around the time of surgery

Conclusions

Chapter 27: What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?

Treat the patient earlier in their disease course

Use concomitant immune modulation and commit to maintenance therapy.

Confirm active inflammation

Defining primary nonresponse to anti-TNF therapy

Management of the Patient with Primary Nonresponse to TNF inhibitors

Management of the patient with secondary loss of response or simple relapse

Conclusions

Chapter 28: Which extraintestinal manifestations of IBD respond to biologics?

Musculoskeletal EIMs

Skin manifestations

Oral manifestations

Ocular complications of IBD

Hepatobiliary complications of IBD

Conclusion

Chapter 29: Use and abuse of biologics in pregnancy.

Use of biologics during pregnancy

Use of biologics and breastfeeding (see Chapter 20)

Use of biologics and newborn management

Conclusions

Chapter 30: Is anti-TNF therapy safe to use in people with a history of malignancy?

Introduction

What is the risk of malignancy in patients treated with anti-TNF antibodies?

What is the risk of cancer recurrence or progression after anti-TNF therapy?

Should patients with previous malignancy be treated with anti-TNF therapy?

Chapter 31: The risks of immunomodulators and biologics: what should we tell patients?

Introduction

What to tell patients about possible side effects

How to tell patients about the risk of side effects

Conclusion

Chapter 32: When, how, and in whom should we stop biologics?

Introduction

Reasons for stopping anti-TNF

Available studies on anti-TNF treatment cessation in IBD

Practical considerations when stopping anti-TNF treatment in CD

Conclusions

Part V: Other Treatments

Chapter 33: Avoiding drug interactions

Introduction

Drug interactions

Warfarin

Smoking cessation

Conclusion

Chapter 34: Is there still a role for ursodeoxycholic acid treatment in patients with inflammatory bowel disease associated with primary sclerosing cholangitis?

Introduction

The PSC-IBD relationship

Effectiveness of UDCA in PSC

Chemopreventive effect of UDCA

Conclusions

Chapter 35: Stem cell transplantation for Crohn's: will it fulfill its promise?

Introduction

What are stem cells?

Rationale for stem cell transplantation in Crohn's disease

Hematopoietic stem cell transplantation

Safety of HSCT in Crohn's disease

Mesenchymal stem cell transplantation

Conclusions

Chapter 36: Complementary therapy: is there a needle in the haystack?

How often and why is CAM used in IBD?

Conclusions

Part VI: Surgical Dilemmas in IBD

Chapter 37: Optimizing IBD patients for surgery and recovery

Introduction

Preoperative care

Operative care

Postoperative care

Chapter 38: Is surgery the best initial treatment for limited ileocecal

Crohn's disease?

Introduction

Conclusion

Chapter 39: Laparoscopic or open surgery for IBD?

Introduction

Laparoscopy for Crohn's disease

Conclusion

Chapter 40: Optimizing management of perianal Crohn's disease

Introduction

Skin tags and hemorrhoids

Strictures

Fissures

Perianal abscesses

Fistulizing disease

Conclusions

Chapter 41: Does anti-TNF therapy increase the risk of complications of surgery?

Introduction

Crohn's Disease

Combined cohorts

Conclusion

Chapter 42: Pouches for indeterminate colitis and Crohn's disease: act now, pay later?

Indeterminate colitis

Crohn's disease

Conclusion

Chapter 43: Dealing with pouchitis

Introduction

Investigation

Treatment (see Figure 43.1 [3])

Preventing initial onset of pouchitis

Implications of use of antibiotics in patients with pouchitis

Part VII: Unsolved Issues in IBD

Chapter 44: Mucosal healing in IBD: does it matter?

Crohn's disease

Ulcerative colitis

Conclusions

Chapter 45: Vitamin D in IBD: from genetics to bone health via cancer and immunology

Vitamin D In IBD: from genetics to bone health via cancer and immunology

Conclusion

Chapter 46: Got milk? Medication use and nursing in women with IBD

Introduction

Effect of nursing on course of IBD

Problems and unresolved issues

Chapter 47: Does stress matter?

Introduction

Plausible mechanisms by which stress can increase gut inflammation

Conclusion

Chapter 48: IBS is common in IBD: fact or fallacy?

Introduction

What is IBS?

Chapter 49: So where is all the cancer?

Colorectal cancer in IBD remains an unsolved issue

Conclusion

A glance into the future

Part VIII: Nutrition in IBD

Chapter 50: What should patients with IBD eat?

Intervention studies

Malnutrition in IBD

“Best current advice”

Need for future work

Chapter 51: Enteral nutrition in Crohn’s—who for, when, how and which formula?

Diet and risk of IBD

Conclusions

Chapter 52: Optimizing treatment of iron deficiency anemia

Introduction

Anemia in IBD

Screening

Diagnostics

Therapy

Intravenous iron supplementation

Further therapy options

Conclusion

Part IX: Management Process

Chapter 53: IBD Standards: will they enhance patient care?

Quality of care: an overview

Quality of IBD care

Defining IBD standards: structure, process, and outcomes

Current efforts to define IBD standards

Future directions: using quality measures to enhance care

Chapter 54: Your treatment will not work if the patient does not take it

Introduction

Nonadherence to maintenance treatment in IBD

The perceptions and practicalities approach (PPA) [9]

Implications for practice

Conclusion

Chapter 55: Inflammatory bowel disease: what to tell your emergency department (ED) team

Introduction

The scale of the problem

Reasons for ER attendance

Approach to the patient with IBD presenting as an emergency

Non-IBD related attendances to ER

How to improve emergency care for patients with IBD

Chapter 56: Transitioning from pediatric to adult care

Introduction

Barriers

The transition process

Conclusion

Chapter 57: Medicolegal pitfalls in inflammatory bowel disease care

Introduction

Conclusions

Index

Clinical Dilemmas in

Inflammatory Bowel Disease

New Challenges

Second Edition

EDITED BY

Peter M. Irving MD, MRCP

Consultant Gastroenterologist
Department of Gastroenterology
Guy's and St Thomas' Hospitals
London, UK

Corey A. Siegel MD, MS

Assistant Professor of Medicine and The Dartmouth Institute for Health Policy and Clinical Practice;
Dartmouth Medical School
Director, Inflammatory Bowel Disease Center
Dartmouth-Hitchcock Medical Center
Section of Gastroenterology and Hepatology
Lebanon, NH, USA

David S. Rampton DPhil, FRCP

Professor of Clinical Gastroenterology
Centre for Digestive Diseases
Barts and The London School of Medicine and Dentistry
London, UK

Fergus Shanahan MD

Professor and Chair
Department of Medicine
Director, Alimentary Pharmabiotic Centre
University College Cork
National University of Ireland
Cork, Ireland

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2011 © 2006, 2011 Blackwell Publishing Ltd.

Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical and Medical business to form Wiley-Blackwell.

Registered office:

John Wiley & Sons, Ltd, The Atrium, Southern Gate,
Chichester, West Sussex,
PO19 8SQ, UK

Editorial offices:

9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19
8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any

product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work.

Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Clinical dilemmas in inflammatory bowel disease : new challenges / edited by Peter Irving ... [et al.]. - 2nd ed.
p. ; cm.

Includes bibliographical references and index.

ISBN-13: 978-1-4443-3454-8 (pbk. : alk. paper)

ISBN-10: 1-4443-3454-9 (pbk. : alk. paper)

ISBN-13: 978-1-4443-4254-3 (ePDF)

ISBN-13: 978-1-4443-4257-4 (e-ISBN-10: : Wiley Online Library) [etc.]

1. Inflammatory bowel diseases. 2. Inflammatory bowel diseases--Decision making.

I. Irving, Peter, 1970-

[DNLM: 1. Inflammatory Bowel Diseases. WI 420]

RC862.I53C553 2011

616.3'44-dc22

2011007515

A catalogue record for this book is available from the British Library.

This book is published in the following electronic formats:

ePDF 9781444342543; Wiley Online Library

9781444342574; ePub 9781444342550; Mobi

9781444342567

Contributors

Ashwin N. Ananthakrishnan MD, MPH

Instructor in Medicine
Harvard Medical School
Gastrointestinal Unit
Massachusetts General Hospital
Boston, MA, USA

Donna Appleton MD, MRCS

Specialist Registrar
Department of General and Colorectal Surgery
Stafford General Hospital
Stafford, UK

Judith E. Baars MSc, PhD Medical Student

Erasmus University
Rotterdam, The Netherlands
Department of Gastroenterology and Hepatology
Erasmus MC Hospital
Rotterdam, The Netherlands

Jacques Belaiche PhD

Professor of Gastroenterology
Department of gastroenterology
CHU Liège and GIGA Research University of Liège
Liège, Belgium

David G. Binion MD

Visiting Professor of Medicine
Division of Gastroenterology, Hepatology, and Nutrition
University of Pittsburgh School of Medicine

Pittsburgh, PA, USA

Wojciech Blonski MD, PhD

Research Scholar
Division of Gastroenterology
University of Pennsylvania
Philadelphia, PA, USA;
Department of Gastroenterology
Medical University
Wroclaw, Poland

Brian Bressler MD, MS, FRCPC

Clinical Assistant Professor of Medicine
Division of Gastroenterology
University of British Columbia
Vancouver, BC, Canada

Emma Calabrese MD, PhD

University of Rome "Tor Vergata"
Rome, Italy

Adam S. Cheifetz MD

Assistant Professor of Medicine;
Clinical Director, Center for Inflammatory Bowel Disease
Division of Gastroenterology
Beth Israel Deaconess Medical Center and Harvard Medical
School
Boston, MA, USA

Dorothy K.L. Chow MBChB, MD, MRCP

Clinical Assistant Professor (Honorary)
Department of Medicine and Therapeutics
Prince of Wales Hospital
The Chinese University of Hong Kong

Hong Kong SAR, China

Miranda Clark BSc(Hons)

Clinical Trials Coordinator
University Hospital
Queen's Medical Centre
Nottingham, UK

Norman R. Clark III MD

Division of Gastroenterology
Vanderbilt University Medical Center
Nashville, TN, USA

Morven Cunningham MA(Hons), MBBS, MRCP

Clinical Research Fellow
Blizard Institute of Cell and Molecular Science
Barts and The London School of Medicine and Dentistry
Queen Mary, University of London
UK

Andrew S. Day MB,ChB, MD, FRACP, AGAF

Associate Professor
Department of Paediatrics
University of Otago
Dunedin, Otago, New Zealand;
Pediatric Gastroenterology
Christchurch Hospital
Christchurch, New Zealand

Alan N. Desmond MB, BCh, BAO, BMedSc, MRCPI

Specialist Registrar
Department of Gastroenterology and General Internal
Medicine
Cork University Hospital

Wilton, Cork, Ireland

Shane M. Devlin MD, FRCPC

Clinical Assistant Professor
Division of Gastroenterology
Inflammatory Bowel Disease Clinic
The University of Calgary
Calgary, AB, Canada

Geert D'Haens MD, PhD

Professor of Medicine
Academic Medical Centre
Amsterdam, The Netherlands

Axel Dignass MD, PhD, FEBG, AGAF

Professor of Medicine
Head, Department of Medicine I
Markus Hospital
Frankfurt/Main, Germany

Glen A. Doherty MB, PhD, MRCPI

Consultant Gastroenterologist
Centre for Colorectal Disease
St Vincent's University Hospital/University College Dublin
Dublin, Ireland

Marla C. Dubinsky MD

Associate Professor of Pediatrics
Director, Pediatric IBD Center
Cedars Sinai Medical Center
Los Angeles, CA, USA

Tim Elliott MBBS, FRACP

Specialist Registrar
Department of Gastroenterology